Development of PET radiopharmaceuticals and their clinical applications at the Positron Medical Center.
The Positron Medical Center has developed a large number of radiopharmaceuticals and 36 radiopharmaceuticals have been approved for clinical use for studying aging and geriatric diseases, especially brain functions. Positron emission tomography (PET) has been used to provide a highly advanced PET-based diagnosis. The current status of the development of radiopharmaceuticals, and representative clinical and methodological results are reviewed.
Ishiwata
Kiichi
K
Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. ishiwata@pet.tmig.or.jp
Kimura
Yuichi
Y
Oda
Keiichi
K
Ishii
Kenji
K
Sakata
Muneyuki
M
Kawasaki
Keiichi
K
Nariai
Tadashi
T
Suzuki
Yukihisa
Y
Ishibashi
Kenji
K
Mishina
Masahiro
M
Hashimoto
Masaya
M
Ishikawa
Masatomo
M
Toyohara
Jun
J
D000544:Alzheimer Disease / Q000000981:diagnostic imaging*; D001921:Brain / Q000098:blood supply; D005947:Glucose / Q000378:metabolism; D006801:Humans; D018482:Muscle, Skeletal / Q000000981:diagnostic imaging; D020734:Parkinsonian Disorders / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D043682:Receptor, Adenosine A1 / Q000502:physiology; D043705:Receptor, Adenosine A2A / Q000502:physiology; D018047:Receptors, Purinergic P1 / Q000502:physiology; D017480:Receptors, sigma / Q000502:physiology; D012039:Regional Blood Flow
D019275:Radiopharmaceuticals; D043682:Receptor, Adenosine A1; D043705:Receptor, Adenosine A2A; D018047:Receptors, Purinergic P1; D017480:Receptors, sigma; D005947:Glucose